Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy

Joseph M. Caster; Cameron Callaghan; Steven N. Seyedin; Kelly Henderson; Bo Sun; Andrew Z. Wang

doi:10.1016/j.addr.2019.07.009

Back

Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy

Journal article

Open access

Peer reviewed

Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy

Joseph M. Caster, Cameron Callaghan, Steven N. Seyedin, Kelly Henderson, Bo Sun and Andrew Z. Wang

Advanced drug delivery reviews, Vol.144, pp.3-15

04/2019

DOI: 10.1016/j.addr.2019.07.009

PMID: 31330165

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/11849717View

Open Access

Abstract

Cancer immunotherapy is one of the fastest growing and most promising fields in clinical oncology. T-cell checkpoint inhibitors are revolutionizing the management of advanced cancers including non-small cell lung cancer and melanoma. Unfortunately, many common cancers are not responsive to these drugs and resistance remains problematic. A growing number of novel cancer immunotherapies have been discovered but their clinical translation has been limited by shortcomings of conventional drug delivery. Immune signaling is tightly-regulated and often requires simultaneous or near-simultaneous activation of multiple signals in specific subpopulations of immune cells. Nucleic acid therapies, which require intact intracellular delivery, are among the most promising approaches to modulate the tumor microenvironment to a pro-immunogenic phenotype. Advanced nanomedicines can be precisely engineered to overcome many of these limitations and appear well-poised to enable the clinical translation of promising cancer immunotherapies. [Display omitted]

Cancer Immunotherapy

Immunotherapy

Nanomedicine

Nanoparticle

Details

Title: Subtitle: Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy
Creators: Joseph M. Caster - University of Iowa
Cameron Callaghan - University of Iowa
Steven N. Seyedin - University of Iowa
Kelly Henderson - University of Iowa
Bo Sun - University of North Carolina at Chapel Hill
Andrew Z. Wang - University of North Carolina at Chapel Hill
Resource Type: Journal article
Publication Details: Advanced drug delivery reviews, Vol.144, pp.3-15
DOI: 10.1016/j.addr.2019.07.009
PMID: 31330165
NLM abbreviation: Adv Drug Deliv Rev
ISSN: 0169-409X
eISSN: 1872-8294
Publisher: Elsevier B.V
Grant note: name: National Institutes of Health/National Cancer Institute, award: U54CA198999, R01 EB25651; DOI: 10.13039/100000005, name: Department of Defense, award: W81XWH-16-1-0530; name: The University of North Carolina’s Research Opportunities Initiative grant
Language: English
Date published: 04/2019
Academic Unit: Radiation Oncology
Record Identifier: 9984312972702771

Metrics

5 Record Views

43 Times Cited - Web of Science